Table II.
Comparison of the therapeutic effects and discontinuation of treatment between the HAIC- and sorafenib-treated groupsa.
| Decision case (%) | HAIC (n=45) | Sorafenib (n=20) | P-valueb |
|---|---|---|---|
| Effect: overall response | |||
| Complete response (CR) | 2 (4.4) | 0 (0.0) | 0.150 |
| Partial response (PR) | 8 (17.8) | 0 (0.0) | |
| Stable disease (SD) | 21 (46.7) | 13 (65.0) | |
| Progressive disease (PD) | 14 (31.1) | 7 (35.0) | |
| ORR (CR+PR) | 10 (22.2) | 0 (0.0) | 0.030 |
| DCR (CR+PR+SD) | 31 (68.8) | 13 (65.0) | 0.780 |
| Discontinuation/continuation | 41 (91.1)/4 (8.9) | 19 (95.0)/1 (5.0) | 1.000 |
| Reason of discontinuation | |||
| Disease progression | 41 (91.1) | 7 (35.0) | <0.001 |
| Side effects | 0 (0.0) | 12 (60.0) | |
| Liver dysfunction | 0 | 3 | |
| Skin disorder | 0 | 4 | |
| Diarrhea | 0 | 4 | |
| Hepatic encephalopathy | 0 | 1 |
a
Date are presented as number (proportions).
b
P-values were obtained by Fisher’s exact test as appropriate. HAIC, hepatic arterial infusion chemotherapy; ORR, overall response rate; DCR, disease control rate.